Hot Investor Mandate 1: Australia Family Office Looks Worldwide for Phase II Biotech Opportunities

27 Jul

A family office based in Australia focuses on late stage therapeutics. The firm manages a $2.5 billion evergreen fund, and typically invests between $1 and $10 million. The firm normally makes co-investments in the USA, Europe, Middle East, and Australia.

The firm is currently looking for new investment opportunities in therapeutics space. The firm is only interested in later stage technology at Phase II or later. The firm is open to all subsectors and indications in therapeutics, though is not interested in lab equipment and drug development enabling technology. The firm does not invest in pre-clinical products, and only seeks products that are either in clinical trials (Phase II or later) with human data or on-the-market.

The firm seeks companies with an established management team with experience in the field. The firm does not typically take a board seat after an investment. The firm seeks distribution rights for Australia and Southeast Asia from international companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: